Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Fiche publication
Date publication
mai 2019
Journal
Clinical colorectal cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher, Pr BORG Christophe, Pr CONROY Thierry, Pr GHIRINGHELLI François, Pr MANTION Georges, Dr SPAETH Dominique, Dr LAKKIS Zaher
Tous les auteurs :
Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T
Lien Pubmed
Résumé
Recurrence and distant metastases remain a significant issue in locally advanced rectal cancer (LARC). Several multimodal strategies are assessed in clinical trials.
Mots clés
Bevacizumab, Fistula, Neoadjuvant chemotherapy, Radiotherapy, Rectal cancer
Référence
Clin Colorectal Cancer. 2019 May 3;: